Table 1. Drug Molecules Used in Docking Analysis and Selected Propertiesa.
| drug | IC50 (ref) | Y652/F656 (ref) | inactivation (ref) |
|---|---|---|---|
| S-bupivacaine | 13 μM (56) | yes (57) | yes (58) |
| cavalli-2 | 17 nM (33) | n.a. | n.a. |
| cavalli-6 | 2.4 nM (33) | n.a. | n.a. |
| cisapride | 21 nM (59) | yes (1753) | yes (48) |
| chloroquine | 2.2 μM (60) | yes (62) | yes (weak) (61) |
| dofetilide | 5 nM (63) | yes (52) | yes (12) |
| E-4031 | 13 nM (64) | yes (52) | yes (10) |
| haloperidol | 27 nM (63) | yes (47) | yes (46) |
| terfenadine | 7 nM (65) | yes (17, (53)) | yes (12) |
a
The IC50 values are taken from the references cited. All IC50 data were obtained by patch clamp at 34–37 °C of human embryonic kidney (HEK) or Chinese hamster ovary (CHO) cells overexpressing hERG. The table also represents whether IC50 values are reduced by attenuation of inactivation (“inactivation”) and in Y652A and F656A hERG mutants (“Y652/F656”). n.a., data not available.